For years, protein engineering was a renovation business. Scientists took a scaffold that nature had already built and tinkered with surface residues, hoping to coax out a new function. The blueprint constrained the result. Generative AI has rewritten that contract. With ProteinMPNN, sequences could be redesigned with a 52.4% native recovery rate that left Rosetta well behind. With RFdiffusion, full backbones could be denoised into existence, including symmetric oligomers, motif scaffolds, and picomolar binders, with the latter confirmed by cryo-EM at near-atomic accuracy. In eighteen months, the toolkit moved from sequence-on-scaffold to scaffold-from-prompt.

What is striking now is how quickly that capability has become an industry. Generative protein design is no longer the private resource of a handful of academic groups; it is a competitive software market with a clear bench-to-pipeline value proposition. A growing list of platforms is vying for biopharma attention, each making different bets on user experience, data strategy, and the underlying model stack. Some embed AI on top of familiar physics-based pipelines; others abandon Rosetta scoring entirely in favour of end-to-end deep generative models. All of them face the same downstream constraint.

“In a manner analogous to networks that produce images from user-specified inputs, RFdiffusion enables the design of diverse functional proteins from simple molecular specifications.”

That capability now reaches scientists through commercial platforms with very different approaches. Latent Labs’ Latent-X is a frontier all-atom binder model offering 91 to 100 percent lab hit rates for macrocycles and picomolar affinities for mini-binders, accessed through a no-code browser interface. Cradle couples its own wet-lab data flywheel with bespoke generative models, and counts six of the top twenty-five global pharmas among customers running active programmes on the platform. Levitate Bio, spun out from Cyrus Biotechnology and David Baker’s lab via the Rosetta Commons Foundation, fuses Rosetta physics with the latest AI protocols for de novo design and developability assessment.

Other entrants are reshaping the workflow itself. Tamarind Bio aggregates over 250 models, among them AlphaFold, RFdiffusion, ProteinMPNN, and GROMACS, into a single orchestrated cloud used by tens of thousands of researchers and eight of the top twenty pharmas. France’s Amineo combines physics, robotics-inspired conformational sampling, and automated reasoning to design custom enzymes and binders from first principles. AminoAnalytica’s Amina is an agentic interface that turns a natural-language brief such as ‘design me a thermostable mini-binder against target X’ into an executed pipeline. The new architects are not merely better tools; they constitute an industrial stack assembling around the Nobel-recognised foundations laid by the Baker lab. For drug discovery, the implication is direct: design space has expanded faster than experimental capacity, and the bottleneck has shifted firmly back to the wet lab.